Math models may tame chemo side effects in breast cancer
NCT ID NCT02392845
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested whether using mathematical models to schedule chemotherapy drugs docetaxel and epirubicin could reduce severe side effects in 17 patients with metastatic breast cancer. The goal was to find the safest dose and schedule while still giving six cycles of treatment. Researchers focused on managing toxicities like vomiting and mouth sores, not on curing the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
docetaxel and epirubicin (chemotherapy drugs)
What this could lead to
If successful, this approach could help doctors give stronger chemotherapy doses more safely by using math models to reduce severe side effects.
What could go wrong
This is a very early, small phase 1 trial with only 17 participants, so results may not apply broadly. The main goal was safety, not effectiveness against cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gilles FREYER , Professor 04 78 86 43 18 Ext. +33 [email protected]
Lyon, 69002, France